Literature DB >> 18347155

Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice.

Yuji Takei1, Yasushi Saga, Hiroaki Mizukami, Takeshi Takayama, Michitaka Ohwada, Keiya Ozawa, Mitsuaki Suzuki.   

Abstract

The main mode of progression of ovarian cancer is peritoneal dissemination, and its inhibition may lead to improved outcome. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) reportedly inhibits the proliferation, migration, and invasion of cancer cells. The purpose of this study is to explore the possibility of PTEN gene therapy for ovarian cancer. We transfected the ovarian cancer cell line SHIN-3 [vascular endothelial growth factor (VEGF)-hypersecretory cell line] with PTEN or luciferase (LUC)-expressing plasmid. After selection, PTEN-overexpressing cells (SHIN-3/PTEN) and control cells (SHIN-3/LUC) were obtained. SHIN-3/PTEN implanted s.c. into nude mice was examined for the change in tumor diameter and the number of new blood vessels. Mice with peritoneally disseminated tumors created by i.p. inoculation of the same cells were examined for changes in body weight and abdominal circumference and for survival time. The growth of s.c. SHIN-3/PTEN was significantly lower than that of control (P < 0.001). Compared with controls, mice with i.p. inoculated SHIN-3/PTEN showed significantly smaller increases in the body weight and abdominal circumference (P < 0.01) and a significantly longer survival time (P < 0.05). VEGF concentration in the supernatant of SHIN-3/PTEN was about half that of controls (P < 0.05). The number of new blood vessels in SHIN-3/PTEN was significantly smaller than that in controls (P < 0.001). Overexpression of PTEN suppressed tumor growth and peritoneal dissemination of VEGF-hypersecretory ovarian cancer cells and prolonged the survival time of the mice with peritoneal disseminated tumor. PTEN gene therapy could have therapeutic potential for ovarian cancer and exerts some of this effect by inhibiting angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347155     DOI: 10.1158/1535-7163.MCT-06-0724

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  14 in total

1.  A mixture copula Bayesian network model for multimodal genomic data.

Authors:  Qingyang Zhang; Xuan Shi
Journal:  Cancer Inform       Date:  2017-04-12

2.  Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis.

Authors:  Haizhi Huang; Allen Y Chen; Yon Rojanasakul; Xingqian Ye; Gary O Rankin; Yi Charlie Chen
Journal:  J Funct Foods       Date:  2015-05-01       Impact factor: 4.451

Review 3.  Targeting the "hallmarks of aging" to slow aging and treat age-related disease: fact or fiction?

Authors:  Maryam Keshavarz; Kan Xie; Kristina Schaaf; Daniele Bano; Dan Ehninger
Journal:  Mol Psychiatry       Date:  2022-07-15       Impact factor: 13.437

4.  PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.

Authors:  Babette Schade; Trisha Rao; Nathalie Dourdin; Robert Lesurf; Michael Hallett; Robert D Cardiff; William J Muller
Journal:  J Biol Chem       Date:  2009-05-12       Impact factor: 5.157

5.  Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction.

Authors:  Akram Sadeghirizi; Razieh Yazdanparast; Safiyeh Aghazadeh
Journal:  Tumour Biol       Date:  2015-12-10

6.  The Role of PTEN in Tumor Angiogenesis.

Authors:  Stéphane Rodriguez; Uyen Huynh-Do
Journal:  J Oncol       Date:  2011-09-05       Impact factor: 4.375

7.  The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.

Authors:  Dongdong Wang; Yasushi Saga; Naoto Sato; Toshikazu Nakamura; Osamu Takikawa; Hiroaki Mizukami; Shigeki Matsubara; Hiroyuki Fujiwara
Journal:  Int J Oncol       Date:  2016-04-14       Impact factor: 5.650

8.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

9.  Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells.

Authors:  Yi-Jing Tao; Yong-Ju Li; Wen Zheng; Juan-Juan Zhao; Meng-Meng Guo; Ya Zhou; Na-Lin Qin; Jing Zheng; Lin Xu
Journal:  Cancer Cell Int       Date:  2015-08-01       Impact factor: 5.722

10.  Overexpressing TPTE2 (TPIP), a homolog of the human tumor suppressor gene PTEN, rescues the abnormal phenotype of the PTEN-/- mutant.

Authors:  Daniel F Lusche; Emma C Buchele; Kanoe B Russell; Benjamin A Soll; Michele I Vitolo; Michael R Klemme; Deborah J Wessels; David R Soll
Journal:  Oncotarget       Date:  2018-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.